La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Cann Group Crescita futura

Future criteri di controllo 0/6

Al momento non disponiamo di una copertura analitica sufficiente per prevedere la crescita e il fatturato di Cann Group.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	28.4%
Tasso di crescita dei ricavi	n/a
Rendimento futuro del capitale proprio	n/a
Copertura analitica	None
Ultimo aggiornamento	n/a

Aggiornamenti recenti sulla crescita futura

Recent updates

Shareholders May Be A Bit More Conservative With Cann Group Limited's (ASX:CAN) CEO Compensation For Now

Nov 03

Here's Why We're Not Too Worried About Cann Group's (ASX:CAN) Cash Burn Situation

Feb 23

What Type Of Returns Would Cann Group's(ASX:CAN) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Nov 25

One Forecaster Is Now More Bearish On Cann Group Limited (ASX:CAN) Than They Used To Be

Nov 25

In questa sezione di solito presentiamo le proiezioni di crescita dei ricavi e degli utili basate sulle stime di consenso degli analisti professionisti per aiutare gli investitori a capire la capacità della società di generare profitti. Tuttavia, poiché Cann Group non ha fornito dati sufficienti sul passato e non ha previsioni degli analisti, i suoi utili futuri non possono essere calcolati in modo affidabile estrapolando i dati passati o utilizzando le previsioni degli analisti.

Si tratta di una situazione piuttosto rara, dato che il 97% delle società coperte da SimplyWall St dispone di dati finanziari passati.

Previsioni di crescita degli utili e dei ricavi

ASX:CAN - Stime future degli analisti e dati finanziari passati (AUD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2023	21	-29	-20	-17	N/A
9/30/2023	21	-32	-23	-20	N/A
6/30/2023	21	-34	-26	-23	N/A
3/31/2023	18	-35	-30	-25	N/A
12/31/2022	14	-37	-35	-28	N/A
9/30/2022	13	-32	-50	-24	N/A
6/30/2022	11	-26	-66	-20	N/A
3/31/2022	10	-25	-68	-17	N/A
12/31/2021	9	-24	-70	-14	N/A
9/30/2021	9	-25	-54	-18	N/A
6/30/2021	9	-25	-37	-21	N/A
3/31/2021	7	-22	-32	-22	N/A
12/31/2020	6	-18	-26	-22	N/A
9/30/2020	4	-17	-39	-20	N/A
6/30/2020	2	-17	-52	-18	N/A
3/31/2020	2	-16	-58	-14	N/A
12/31/2019	3	-14	-64	-10	N/A
9/30/2019	3	-13	-48	-9	N/A
6/30/2019	3	-11	-33	-7	N/A
3/31/2019	2	-10	-23	-7	N/A
12/31/2018	1	-8	-13	-7	N/A
9/30/2018	1	-6	-11	-5	N/A
6/30/2018	1	-5	-9	-4	N/A
3/31/2018	0	-4	-7	-3	N/A
12/31/2017	0	-3	-5	-2	N/A
9/30/2017	0	-3	N/A	-2	N/A
6/30/2017	0	-3	N/A	-2	N/A
6/30/2016	0	-1	N/A	-1	N/A
6/30/2015	0	-4	N/A	-1	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Dati insufficienti per determinare se la crescita degli utili prevista CAN è superiore al tasso di risparmio ( 2.4% ).

Guadagni vs Mercato: Dati insufficienti per determinare se si prevede che gli utili di CAN cresceranno più velocemente del mercato Australian

Guadagni ad alta crescita: Dati insufficienti per determinare se si prevede che gli utili di CAN cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Dati insufficienti per determinare se si prevede che i ricavi di CAN cresceranno più rapidamente del mercato Australian.

Ricavi ad alta crescita: Dati insufficienti per determinare se si prevede che i ricavi di CAN cresceranno più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di CAN è previsto essere elevato tra 3 anni

Cann Group Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Cann Group Limited Provides Revenue Guidance for the Year Ended June 30, 2023

Cann Group Limited Revises Revenue Guidance for the Year 2021

Price target lowered to AU$1.12

Analysts update estimates

Recent updates

Cann Group Limited to Report Fiscal Year 2024 Results on Aug 30, 2024

Cann Group Limited Appoints Jenni Pilcher as Managing Director

Less than half of directors are independent

Cann Group Limited's (ASX:CAN) Low P/S No Reason For Excitement

New major risk - Financial position

Cann Group Limited Appoints Tony Di Pietro as Joint Company Secretary of Head of Legal and Regulatory Affairs

A Piece Of The Puzzle Missing From Cann Group Limited's (ASX:CAN) Share Price

Cann Group Limited Announces Resignation of Deborah Ambrosini as Chief Financial Officer, Effective December 22, 2023

Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.3756 million.

Cann Group Limited, Annual General Meeting, Oct 26, 2023

Full year 2023 earnings released: AU$0.091 loss per share (vs AU$0.079 loss in FY 2022)

New minor risk - Financial data availability

Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 11.658446 million.

Cann Group Limited Provides Revenue Guidance for the Year Ended June 30, 2023

Cann Group (ASX:CAN) Is Making Moderate Use Of Debt

First half 2023 earnings released: AU$0.053 loss per share (vs AU$0.028 loss in 1H 2022)

Cann Group Limited Announces Preliminary Results from Their Phase 3 Clinical Trail

Cann Group Limited Announces Chief Executive Officer Changes

Cann Group Limited Announces Final Clinical Trial Participant Completes Study

Less than half of directors are independent

Cann Group Limited Appoints Julian John Chick as Director

Cann Group Limited Announces Resignation of Peter Crock as CEO

Cann Group Limited Meets its Enrolment Target for Phase III Clinical Trial of Low-Dose Satipharm CBD Capsules for Short-Term Sleep Disturbance

Cann Group Limited Announces Executive Changes

Cann Group Limited Appoints Robert Barnes & Julian Chick to the Board

Cann Group Limited Announces Resignation of John Sharman as Director

Cann Group Limited, Annual General Meeting, Oct 25, 2022

Full year 2022 earnings released: AU$0.079 loss per share (vs AU$0.098 loss in FY 2021)

Cann Group Limited Announce Therapeutic Goods Administration Grants Cann GMP License to Manufacture Therapeutic Goods

Cann Group Limited Receives Second Payment from Victorian Government's Regional Jobs Fund Program

Less than half of directors are independent

Office of Drug Control Grants Permit for Manufacture of Medicinal Cannabis Products to Cann Group Limited

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Cann Group Limited Announces Resignation of Mr. Geoffrey Pearce as Non-Executive Director

Cann Group Limited Announces Cann to Begin Recruitment for CBD Phase 3 Clinical Trial

Rua Bioscience Limited (NZSE:RUA) agreed to acquire 8.36% stake in Zalm Therapeutics Ltd from Cann Group Limited (ASX:CAN) for NZD 10 million.

Shareholders May Be A Bit More Conservative With Cann Group Limited's (ASX:CAN) CEO Compensation For Now

Chief Financial Officer Greg Bullock has left the company

Full year 2021 earnings released: AU$0.097 loss per share (vs AU$0.12 loss in FY 2020)

Cann Group Limited Revises Revenue Guidance for the Year 2021

Cann Group Limited (ASX:CAN) completed the acquisition of Satipharm Ltd, Satipharm AG and Phytotech Therapeutics Ltd from Harvest One Cannabis Inc. (TSXV:HVT)

Cann Group Limited, Olivia Newton-John Cancer Research Institute and Austin Health Partnered in A Clinical Tria to Assess Medicinal Cannabis for Symptom Management in People with Advanced Cancer

Cann Group Limited (ASX:CAN) entered into a definitive sale agreement to acquire Phytotech Therapeutics Ltd from Harvest One Cannabis Inc. (TSXV:HVT).

First half 2021 earnings released: AU$0.05 loss per share (vs AU$0.06 loss in 1H 2020)

Here's Why We're Not Too Worried About Cann Group's (ASX:CAN) Cash Burn Situation

Cann Group Limited (ASX:CAN) signed a share sale agreement to acquire Satipharm Ltd from Harvest One Cannabis Inc. (TSXV:HVT) for CAD 4 million.

New 90-day high: AU$0.78

Australis Capital Inc. and Cann Group Limited Sign Agreement

Price target lowered to AU$1.12

Cann Group Limited Receives Initial 19,000 Unit Order for Europe

What Type Of Returns Would Cann Group's(ASX:CAN) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

One Forecaster Is Now More Bearish On Cann Group Limited (ASX:CAN) Than They Used To Be

Analysts update estimates

New 90-day high: AU$0.51

Deputy Chairman recently bought AU$55k worth of stock

An unknown buyers acquired 11.84% stake in Cann Group Limited (ASX:CAN) from Aurora Cannabis Inc. (TSX:ACB).

New 90-day low: AU$0.38

Cann Group Limited(ASX:CAN) dropped from S&P Global BMI Index

Deputy Chairman recently bought AU$79k worth of stock

Full year earnings released - AU$0.12 loss per share

New 90-day low - AU$0.45

Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 25.9 million.

New 90-day low - AU$0.46

Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 14.3 million.

New 90-day low - AU$0.72

Cann Group Limited(ASX:CAN) dropped from S&P/ASX All Ordinaries Index

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita